Does One Small Biotech Company Hold The Key To Conquering Two Of Mankind’s Most Feared Diseases?


The smart money seems to think so.

The growing interest in INmune Bio (NASDAQ:INMB) is primarily due to its 3 promising therapies now in clinical trial.
2 of these, INBO3 and INKmune, target cancer;
the other, XPro1595, Alzheimer’s.
In addition, one of the world’s leading immunologists says the company’s Alzheimer’s therapy could lead to a breakthrough in the treatment of multiple sclerosis.

The Other Side Of The System

To put it simply, INmune Bio is looking where nobody else is. It’s focused on the other side of the immune system – the innate immune side.

Most people don’t realize that the human body’s immune system has two sides – essentially two immune systems. The adaptive side responds to foreign substances that enter the body; the innate side of the system deals with bad things that are already there.

And because many cancers develop from pre-cancerous cells that are created by the body, the adaptive immune system gives them a pass. Fortunately, the innate system doesn’t.

Its cells seek out and kill these abnormal cells. Which is why they’re called
Natural Killer Cells.

But sometimes these Natural Killer can’t do their job because cancer cells have the uncanny ability to make themselves virtually invisible. Especially those cancer cells left in the body after treatment. INmune Bio solution to the problem is a new product called INKmune™
INKmune™ programs the NK cells to identify these cloaked cancer cells and kill them. Which makes INKmune unlike any other cancer therapy in the world.

INKmune™ is currently approved for Phase 1 clinical trials in Great Britain. Once these results are accepted, the company plans Phase 2 trials in the United States.

As much of a breakthrough as INKmune™ promises to be, it’s not the only cancer weapon in INmune Bio’s arsenal. Of equal importance is …

Cancer Weapons

One of the company’s two lead development products in the fight against cancer is INB03 – a protein biologic that works by inhibiting the activities of  Myeloid-Derived Suppressor Cells (MDSC). These cells create a shield around the patient’s tumor; INB03 strips away this shield so that the body’s Natural Killer cells can attack it.

INBO3 is part of a class of drugs known as checkpoint inhibitors – the market for which is said to be $1 billion in the US alone. At present, existing drugs in this class work in only 25% of patients. If INBO3, proves effective, INmune Bio (NASDAQ:INMB) will likely dominate this market.

The other promising anti-cancer therapy is a product called INKmune™. It primes the body’s Natural Killer (NK) cells to attack cancer cells that might otherwise evade them – because of the uncanny ability of cancer cells to make themselves virtually invisible.

INKmune™ is expected to be especially important in destroying cancer cells left in the body after treatment by surgery or chemotherapy.

INmune Bio’s arsenal isn’t only for combatting cancer, however. It also contains a potential weapon against Alzheimer’s disease.

In recognition of INmune Bio’s revolutionary approach, the Alzheimer’s Association awarded the company a million-dollar “Part the Cloud to RESCUE” grant.

Through The Roof?

Should INmune Bio (NASDAQ:INMB) succeed in just one of its therapies, that’s where its stock would likely go. In biotech, it’s similar to when an oil company makes a discovery. The stocks go BIG.
But because stock in biotech companies can move on data alone, major movement could occur on the outcome of one of INmune Bio’s clinical trials for its therapies. And those are right around the corner.

How other micro-cap biotechs are faring



Readouts of Phase 1 clinical trial results for INBO3 are expected by the end of March. The second half of 2019 Phase 1 readouts on INKmune™ are due soon. Enrollment in Phase 2 trials for INBO3 is scheduled for later this year. And enrollment in Phase 1 trials for XPR01595 is also set for later this year.

An Acquisition Magnet?

INmune Bio (NASDAQ:INMB) would also become a prime target for a buy out. Small, agile biotech companies that are developing disruptive technologies like INmune Bio are always targets for big pharma.

Big pharmaceutical companies don’t innovate – they acquire.

Xencor (XNCR), a pioneer in antibody drugs and INmune Bio’s largest shareholder, has an option to buy another 10% of the company could likely opt for the rest of it. Unless, of course, another deep-pocketed, big pharma company gets there first.

Billion Dollar Buyouts

There’ve been a lot of those in the immune-oncology space lately.

  • – In 2017, Gilead (GILD) bought Kite Pharma (KITE) in a $11.9 Billion deal.
  • Celgene (CELG) acquired Juno (JUNO) for $9 Billion last year.
  • – This year, Bristol-Myers Squibb (BMY) bought Celgene in a $74 Billion deal.
  • And Eli Lilly (LLY) paid close to $8 Billion for Loxo Oncology (LOXO.)

All of the companies bought were developing therapies and were acquired Pre-FDA approval. And every one was working along adaptive immune-oncology lines. Which, so far, haven’t worked.

Just imagine what big pharma would pay for a biotech with a therapy that did?

All of which in our opinion, makes INmune Bio (INMB) an immediate and unequivocal “buy.” But you might want to act fast. Before big pharma gets there.

More Than Making Money

This is one of those rare cases where there’s something even more important than that…

For if even one of the company’s new products proves safe and effective, the treatment of cancer or Alzheimer’s and the lives of millions of people would be forever changed. And the world would be changed … for the better.

If you’d like to be a part of that, while making a lot of money, we’d suggest you start researching INmune Bio now!

For more information on INmuneBio’s (INMB), visit the company’s website and corporate presentation:

Disclosure: The information, opinions and analysis contained in this report are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We do not accept any responsibility or liability for any losses, damages or costs arising from an investor’s or other person’s reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities, nor a recommendation of any security. Past gains are not representative of future gains. Prime IR LLC has been and will be compensated for distribution of its opinions and publicly available information regarding the companies reported in this investment opinion article by INmune Bio inc. as follows:
$10,000 (10%) of INmune Bio Inc. $100,000 online media buying budget that was wired to Prime IR LLC.
Prime IR’s affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event these shares rise in value. Prime IR will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

The opinions contained herein contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. When used herein, the words “anticipate,” “intend,” “estimate,” “believe,” “expect,” “plans,” “should,” “potential,” “forecast,” and variations of such words and similar expressions are intended to identify forward-looking statements. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. A company’s actual results could differ materially from those described in any forward-looking statements contained herein. Prime IR LLC is not a licensed broker, broker dealer, market maker, investment advisor, analyst or underwriter. We recommend that you use the information found herein as an initial starting point for conducting your own research in order to determine your own personal opinion of the companies discussed herein before deciding whether or not to invest. You should seek such investment, tax, financial, accounting or legal advice appropriate for your particular circumstances. Information about many publicly traded companies and other investor resources can be found at Investing in securities is speculative and carries risk. Please visit For more details.